DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Table 31–1
Characteristics of Plasma Lipoproteins
LIPOPROTEIN DENSITY MAJOR LIPID TG:CHOL SIGNIFICANT SITE OF MECHANISM(S) OF
CLASS (g/mL) CONSTITUENT RATIO APOPROTEINS SYNTHESIS CATABOLISM
Chylomicrons <<1.006 Dietary triglycerides 10:1 B-48, E, A-I, A-IV, Intestine Triglyceride hydrolysis
and remnants and cholesterol C-I, C-II, C-III by LPL, apoE-mediated
remnant uptake by liver
VLDL <1.006 “Endogenous” or 5:1 B-100, E, C-I, C-II, Liver Triglyceride
hepatic C-III hydrolysis by LPL
triglycerides
IDL 1.006-1.019 Cholesteryl esters 1:1 B-100, E, C-II, C-III Product of 50% converted to LDL
and “endogenous” VLDL mediated by HL;
triglycerides catabolism 50% apoE-mediated
uptake by liver
LDL 1.019-1.063 Cholesteryl esters NS B-100 Product of ApoB-100–mediated uptake
VLDL
by LDL receptor
catabolism (~75% in liver)
HDL 1.063-1.21 Phospholipids, NS A-I, A-II, E, C-I, Intestine, Complex: transfer of
cholesteryl esters C-II, C-III liver, plasma cholesteryl ester to
VLDL and LDL;
uptake of HDL cholesterol
by hepatocytes
Lp(a) 1.05-1.09 Cholesteryl esters NS B-100, apo(a) Liver Unknown
apo, apolipoprotein; CHOL, cholesterol; HDL, high-density lipoproteins; IDL, intermediate-density lipoproteins; Lp(a), lipoprotein(a); LDL, low-density lipoproteins; NS, not significant (triglyceride
is <5% of LDL and HDL); TG, triglyceride; VLDL, very-low-density lipoproteins; HL, hepatic lipase; LPL, lipoprotein lipase.
CHAPTER 31
DRUG THERAPY FOR HYPERCHOLESTEROLEMIA AND DYSLIPIDEMIA
879